A review of the LexisNexis legal research database identified 21 medical liability cases involving GLP-1 receptor agonists through February 2026, with only six cases occurring since 2021. ^[1] A press release from Eli Lilly reported that adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 52 weeks with tirzepatide plus ixekizumab versus ixekizumab monotherapy. ^[2] Of the 15 cases before 2021, 10 involved failure-to-warn claims related to pancreatitis and pancreatic cancer, whereas the six newer cases involved allegations of commercial fraud or prescribing-related negligence. ^[3] In the TOGETHER-PsA trial, 39.2% of the combination group achieved the primary outcome of 50% or greater reduction in psoriatic arthritis disease activity based on American College of Rheumatology 50 plus at least 10% weight loss by week 52, compared to 1.7% in the monotherapy group. ^[4] In the TOGETHER-PsO trial, more than 40% of participants receiving combination therapy achieved complete skin clearance by week 52 versus 29.1% in the monotherapy group. ^[5]